Clinical trial
Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in…
NCT00193128 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193128 |
|---|---|
| Title | Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer |
| Official title | A Phase I/II Trial of Preoperative Oxaliplatin, Docetaxel, and Capecitabine With Concurrent Radiation Therapy in Localized Carcinoma of the Esophagus or Gastroesophageal Junction |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Sanofi-Synthelabo Industry Aventis Pharmaceuticals |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Esophagus Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Oxaliplatin, Docetaxel, Capecitabine, Radiation therapy |
| Enrollment | 59 |
| Start date | Apr 1, 2004 |
| Primary completion | Feb 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Nov 24, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: